{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:46:53Z","timestamp":1790876813187,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofliquidbiopsy.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Liquid Biopsy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jlb.2026.100477","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:30:36Z","timestamp":1782315036000},"page":"100477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Longitudinal methylated ctDNA increases predict immunotherapy progression across solid tumors"],"prefix":"10.1016","volume":"13","author":[{"given":"Muhammad","family":"Anees","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick L.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashten","family":"Omstead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Grayhack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Sherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee D.","family":"McDaniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2075-3224","authenticated-orcid":false,"given":"Matthew G.","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mohammad Hossein","family":"Hosseiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Laframboise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Krivak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benny","family":"Weksler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Dadgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shurjeel Uddin","family":"Qazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Bahary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali H.","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jlb.2026.100477_bib1","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ctrv.2014.06.012","article-title":"Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma","volume":"40","author":"McDermott","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jlb.2026.100477_bib2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.22.01503","article-title":"Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic Non\u2013small-cell lung cancer in CheckMate 227","volume":"41","author":"Brahmer","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jlb.2026.100477_bib3","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41416-021-01413-x","article-title":"Cancer immunotherapy: it's time to better predict patients' response","volume":"125","author":"Pilard","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jlb.2026.100477_bib4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jlb.2026.100477_bib5","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of neoantigen landscape during immune checkpoint blockade in non\u2013small cell lung cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jlb.2026.100477_bib6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jlb.2026.100477_bib7","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jlb.2026.100477_bib8","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","article-title":"Pseudoprogression and immune-related response in solid tumors","volume":"33","author":"Chiou","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jlb.2026.100477_bib9","doi-asserted-by":"crossref","DOI":"10.1148\/rycan.250019","article-title":"Global cancer imaging access: addressing barriers and harnessing innovations","volume":"7","author":"Hussain","year":"2025","journal-title":"Radiol Imaging Cancer"},{"key":"10.1016\/j.jlb.2026.100477_bib10","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clgc.2023.03.003","article-title":"Pseudoprogression and mixed responses in metastatic renal cell carcinoma patients treated with nivolumab: a retrospective analysis","volume":"21","author":"Haaker","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.jlb.2026.100477_bib11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13244-024-01774-w","article-title":"RECIST 1.1 assessments variability: a systematic pictorial review of blinded double reads","volume":"15","author":"Iannessi","year":"2024","journal-title":"Insights Imaging"},{"key":"10.1016\/j.jlb.2026.100477_bib12","doi-asserted-by":"crossref","first-page":"655","DOI":"10.20892\/j.issn.2095-3941.2019.0144","article-title":"The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy","volume":"16","author":"Jia","year":"2019","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.jlb.2026.100477_bib13","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1158\/1078-0432.CCR-17-1341","article-title":"Early assessment of lung cancer immunotherapy response via circulating tumor DNA","volume":"24","author":"Goldberg","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jlb.2026.100477_bib14","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-18-0386","article-title":"Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab","volume":"24","author":"Raja","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jlb.2026.100477_bib15","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s43018-020-0096-5","article-title":"Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab","volume":"1","author":"Bratman","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jlb.2026.100477_bib16","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/2159-8290.CD-20-0047","article-title":"Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jlb.2026.100477_bib17","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1200\/PO.20.00321","article-title":"Serial monitoring of circulating tumor DNA by next-generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy","volume":"5","author":"Thompson","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jlb.2026.100477_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001504","article-title":"Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)","volume":"9","author":"Ricciuti","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jlb.2026.100477_bib19","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41591-023-02598-9","article-title":"ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results","volume":"29","author":"Anagnostou","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jlb.2026.100477_bib20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1158\/1078-0432.CCR-23-1469","article-title":"Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer","volume":"30","author":"Murray","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jlb.2026.100477_bib21","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/s41591-023-02226-6","article-title":"A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer","volume":"29","author":"Assaf","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jlb.2026.100477_bib22","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1158\/2767-9764.CRC-25-0151","article-title":"Methylation-based ctDNA tumor fraction changes predict long-term clinical benefit from immune checkpoint inhibitors in RADIOHEAD, a real-world pan-cancer study","volume":"5","author":"Liang","year":"2025","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.jlb.2026.100477_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41698-026-01287-3","article-title":"Ultrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer","volume":"10","author":"Nishizaki","year":"2026","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.jlb.2026.100477_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-53711-3","article-title":"Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer","volume":"9","author":"Osumi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jlb.2026.100477_bib25","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/1078-0432.CCR-24-3612","article-title":"ctDNA clearance as an early indicator of improved clinical outcomes in advanced NSCLC treated with TKI: findings from an aggregate analysis of eight clinical trials","volume":"31","author":"Andrews","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jlb.2026.100477_bib26","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1038\/s41416-023-02445-1","article-title":"Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors","volume":"129","author":"Thompson","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jlb.2026.100477_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in Early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jlb.2026.100477_bib28","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.jlb.2026.100477_bib29","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jlb.2026.100477_bib30","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/cells9030624","article-title":"DNA methylation-based testing in liquid biopsies as detection and prognostic biomarkers for the four major cancer types","volume":"9","author":"Const\u00e2ncio","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jlb.2026.100477_bib31","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/2159-8290.CD-23-1060","article-title":"Early changes in tumor-naive cell-free methylomes and fragmentomes predict outcomes in pembrolizumab-treated solid tumors","volume":"14","author":"Stutheit-Zhao","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jlb.2026.100477_bib32","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1038\/s41598-025-90013-3","article-title":"Molecular counting enables accurate and precise quantification of methylated ctDNA for tumor-naive cancer therapy response monitoring","volume":"15","author":"Ye","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.jlb.2026.100477_bib33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12943-022-01551-7","article-title":"A clinician's handbook for using ctDNA throughout the patient journey","volume":"21","author":"Hasenleithner","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jlb.2026.100477_bib34","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.LIQBIOP24-B046","article-title":"Brief report: methylation-based ctDNA serial monitoring correlates with immunotherapy response in NSCLC","author":"Hsiao","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jlb.2026.100477_bib35","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.tibtech.2024.12.003","article-title":"Absolute quantification of cell-free DNA for prenatal genetics and oncology","volume":"43","author":"Tsao","year":"2025","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.jlb.2026.100477_bib36","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/XCS.0000000000000939","article-title":"Methylated ctDNA quantification: noninvasive approach to monitoring hepatocellular carcinoma burden","volume":"238","author":"Angeli-Pahim","year":"2024","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.jlb.2026.100477_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2026.100467","article-title":"Exploring genomic analysis and methylome profiling in longitudinal series of p.G12C KRAS mutated NSCLC patients treated with sotorasib","volume":"12","author":"Pepe","year":"2026","journal-title":"J Liq Biopsy"},{"key":"10.1016\/j.jlb.2026.100477_bib38","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1158\/1078-0432.CCR-19-3015","article-title":"Harmonizing cell-free DNA collection and processing practices through evidence-based guidance","volume":"26","author":"Greytak","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jlb.2026.100477_bib39","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jmoldx.2025.05.007","article-title":"Cell-free DNA, tumor molecular concordance, and clinical correlates of patients with cancer treated in a large community health care network","volume":"27","author":"LaFramboise","year":"2025","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jlb.2026.100477_bib40","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00372","article-title":"Changes in circulating tumor DNA reflect clinical benefit across multiple studies of patients with Non\u2013small-cell lung cancer treated with immune checkpoint inhibitors","author":"Vega","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jlb.2026.100477_bib41","article-title":"Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: evidence from a real-world cohort of patients with advanced common solid malignancies","volume":"10","author":"Rolfo","year":"2025","journal-title":"J Liq Biopsy"},{"key":"10.1016\/j.jlb.2026.100477_bib42","article-title":"Real-world validity of tissue-agnostic circulating tumor DNA response monitoring in lung cancers treated with chemotherapy, immunotherapy, or targeted agents","volume":"6","author":"Chiang","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jlb.2026.100477_bib43","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1200\/JCO.18.01100","article-title":"RECIST 1.1 for response evaluation apply not only to chemotherapy-treated patients but also to targeted cancer agents: a pooled database analysis","volume":"37","author":"Liti\u00e8re","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jlb.2026.100477_bib44","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous Non\u2013small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jlb.2026.100477_bib45","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic Non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jlb.2026.100477_bib46","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/annonc\/mdu239","article-title":"Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle","volume":"25","author":"De Mattos-Arruda","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jlb.2026.100477_bib47","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/ajcp\/aqv023","article-title":"Identification of factors affecting the success of next-generation sequencing testing in solid tumors","volume":"145","author":"Goswami","year":"2016","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jlb.2026.100477_bib48","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jlb.2026.100477_bib49","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the evolution of Non\u2013small-cell lung cancer","volume":"376","author":"Jamal-Hanjani","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jlb.2026.100477_bib50","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"The Tracerx consortium","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jlb.2026.100477_bib51","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.cell.2018.03.057","article-title":"Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal","volume":"173","author":"Turajlic","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.jlb.2026.100477_bib52","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","article-title":"Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA","volume":"616","author":"Abbosh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jlb.2026.100477_bib53","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.medj.2025.100926","article-title":"The comings and goings of cell-free DNA: biological and clinical implications","volume":"7","author":"Malki","year":"2026","journal-title":"Med"}],"container-title":["The Journal of Liquid Biopsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195426000238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195426000238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:30:01Z","timestamp":1789014601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950195426000238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":53,"alternative-id":["S2950195426000238"],"URL":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100477","relation":{},"ISSN":["2950-1954"],"issn-type":[{"value":"2950-1954","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal methylated ctDNA increases predict immunotherapy progression across solid tumors","name":"articletitle","label":"Article Title"},{"value":"The Journal of Liquid Biopsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100477","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of The International Society of Liquid Biopsy.","name":"copyright","label":"Copyright"}],"article-number":"100477"}}